Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New polymer material stops bone bleeding and reduced surgical infection risks

Ceremed : 06 February, 2008  (New Product)
Ostene, a new polymer material developed by Ceremed to stop bone bleeding in surgery has been shown to reduce the risk of surgical infection according to a new research study.
The study has implications for lowering the risk of hospital-acquired infections, including MRSA.

Researchers from the Medical University of South Carolina at Charleston and Keck School of Medicine at the University of Southern California in Los Angeles compared newly available polymer, Ostene, with bone wax, traditionally used to stop bone bleeding in surgically cut bone surfaces.

The scientists looked at the two materials' effect on bone infection in the presence of Staphylococcus Aureus, similar to the organism that is responsible for MRSA. The results showed that, when exposed to bacteria, the bones treated with Ostene were four times less likely to get infected than the bones treated with bone wax, 100 percent of which developed infection.

The study also showed that the bones treated with Ostene healed normally, while the presence of bone wax inhibited bone growth.

Bone wax, a beeswax-based product, is the least expensive and most commonly used bone haemostasis material despite its well-documented side effects: Numerous studies indicate that bone wax interferes with the body's ability to clear bacteria and increases the risk of hospital-acquired infections; it is also known to inhibit bone growth and bone healing after surgery.

Ostene offers an alternative that does not increase the risk to patient. Its use in place of bone wax may help reduce serious post-operative complications, including sternal wound infection and the separation of the sternum.

The material is used in cardiac, orthopaedic, oral, and neurosurgery. Other applications under development include the use of Ostene as a safe, soluble delivery vehicle for a variety of therapeutic agents, from antibiotics to bone growth factors. Ostene is authorised for sale both in the USA and the European market.

Ostene is a sterile mixture of water-soluble alkylene oxide copolymers developed as an affordable, easy-to-handle synthetic bone haemostasis material that reduces the overall risk of post surgical infections, sternal non-union, poor bone healing and chronic inflammation. Wax-like and malleable during application, the Biomaterial dissolves rapidly and is eliminated from the body shortly after surgery.

The material's main polymer component inherently reduces bacterial adhesion. Ostene is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or add the risk of surgical infections, including MRSA.

The results of the USC/MUSC study suggest that the use of Ostene may have implications for reducing the risk of surgical site infection and for improving post-operative healing and recovery. The benefits of Ostene may be significant in lowering the rates of serious complications following cardiac surgery, especially among a growing high-risk group of diabetic and overweight patients, who currently represent at least 25 percent of the 640,000 open heart surgery procedures performed each year in the USA.

'Ostene's unique properties are particularly significant now that we are battling the threat of hospital-acquired infections, especially MRSA,' Ceremed's president and CEO Tadeusz Wellisz, MD, commented on the study. 'Ceremed is currently developing the next generation of Ostene with antibiotics, specifically designed to prevent hospital-acquired surgical infection.'

The results of the study are published in the February 2008 issue of Clinical Orthopaedics and Related Research (CORR).
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo